What Livagen is
Livagen is the tetrapeptide KEDA, marketed as a liver “bioregulator.” It has no FDA-approved product, liver indication, or dose.
Human-derived cells are not a human treatment trial
Studies exposed lymphocytes from older people to Livagen and measured chromatin changes.[1] Other work examined rat hepatocyte cultures and organotypic liver cultures.[2] These findings do not establish improved liver enzymes, fibrosis, fatty-liver disease, hepatitis outcomes, detoxification, or longevity in people.
Safety is unknown
Human absorption, metabolism, adverse events, interactions, liver-injury risk, pregnancy use, and long-term safety are undefined. A substance marketed for “liver support” can still delay diagnosis or conflict with established care.
Regulatory status
Livagen is unapproved in the United States. Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[3] Teloryx publishes no dose or preparation protocol.